Somalogic sales drop, losses mount

BOULDER — SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public last year in a merger with a special purpose acquisition company, has dropped its full-year revenue sales guidance as revenues lagged and losses mounted in the second quarter of 2022. 

The company, which develops platforms to read thousands of proteins in a patient’s blood or urine sample that may signal illnesses or future health conditions and suggest potential treatments via machine learning, posted second quarter 2022 revenues of $14.1 million, a 28.5% decrease from $19.8 million.

Research and development costs, along with other selling, general and administrative expenses,…